ZEDRA
7.1.2020 09:02:07 CET | Business Wire | Press release
ZEDRA Group (“ZEDRA”), the global specialist in Corporate, Fund and ‘Active-Wealth’ services and Corsair Capital LLC (“Corsair”), one of the leading private equity firms focused on the financial and business services industries, today announced the successful close of Corsair’s majority investment in ZEDRA Group. The transaction, which was first announced on November 28, 2018, has been approved by all relevant regulatory authorities.
Following the close of the transaction, Bart Deconinck, a highly experienced industry figure who previously has been CEO of Intertrust and was a founder of Vistra before going on to co found Zedra four years ago, has been appointed Group Executive Chairman. In addition, Ivo Hemelraad, formerly Zedra Group Director Corporate Funds & Legal, will assume the role of Group Chief Executive Officer.
ZEDRA delivers tailored high quality diversified active-wealth solutions to its clients, which include high net worth individuals and their families, as well as medium to large sized companies, asset managers and their investors. ZEDRA’s full range of services is designed to preserve and protect the real value of clients’ assets and support them in unlocking growth and expansion.
Raja Hadji-Touma and Derrick Estes, Managing Directors at Corsair Capital said, “ZEDRA is a unique firm with unparalleled capabilities, and we are pleased to have closed this exciting investment. We look forward to partnering with an ambitious management team, led by Bart Deconinck, with a proven track record of building leading companies in the sector. We believe our investment and financial services expertise, along with the unmatched global network we bring to bear, will help support continued rapid growth at ZEDRA.”
Over the last 12 months, ZEDRA has made a number of important acquisitions, creating an expanded platform with over 570 staff in a 16 office network covering 13 jurisdictions across Asia, Oceania, the Americas and Europe. As the Company continues to integrate these acquisitions, ZEDRA is even better-placed to continue creating and delivering bespoke trust, corporate and fund services solutions for clients including high-net-worth individuals and their families, international corporations, institutional investors and entrepreneurs.
Bart Deconinck, Group Executive Chairman added, “Today marks the start of the next stage of ZEDRA‘s ambitious growth plans. Powered by a combination of the resources and expertise of Corsair, together with ZEDRA’s considerable experience in the sector, we are looking forward to a period of rapid growth and expansion of the range of services we offer to our clients. The major acquisitions we have made over the past year expand our footprint across Switzerland, the Nordic countries, Cayman and offshore UK jurisdictions, bringing additional clients and staff into the ZEDRA family.”
Under its ‘Active - Wealth’ umbrella, ZEDRA provides a single point of contact for the administration of a wide range of assets for families with diversified investments, including the administration of any relevant structures they require, such as their corporate investment ventures, single-family offices, or private funds for various family members.
Ivo Hemelraad commented: “We are delighted to have completed this transaction and to begin our partnership with Corsair Capital. Their commitment and support to ZEDRA’ S growth as well as to our people are an exciting step for ZEDRA to further enhance our offering and position in the industry.”
Editor notes
https://www.zedra.com/boilerplate/
View source version on businesswire.com: https://www.businesswire.com/news/home/20200107005091/en/
Contact:
Guy Stephenson Nacelle 020 8333 9125
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release
Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
